![]()
- Ubiquitylation is a post‑translational modification in which the small regulatory protein ubiquitin is covalently attached to target proteins, altering their stability, activity, localisation, or interactions. This modification is central to protein quality control, signal transduction, DNA repair, immune regulation, and cell‑cycle progression. Because ubiquitylation determines whether proteins are activated, inhibited, or degraded, it is one of the most versatile and influential regulatory mechanisms in modern cell biology. It forms a core concept in ubiquitin signalling and cellular homeostasis.
- Ubiquitylation occurs through a highly coordinated enzymatic cascade involving three classes of enzymes: E1 ubiquitin‑activating enzymes, E2 ubiquitin‑conjugating enzymes, and E3 ubiquitin ligases. E1 enzymes activate ubiquitin in an ATP‑dependent reaction, transferring it to E2 enzymes. E3 ligases then catalyse the final step, attaching ubiquitin to specific substrate proteins. E3 ligases provide substrate specificity, ensuring that only selected proteins are modified. This hierarchical system allows cells to precisely regulate protein fate and respond rapidly to physiological changes.
- Ubiquitylation can occur in several forms. Monoubiquitylation involves the attachment of a single ubiquitin molecule and often regulates protein trafficking, endocytosis, or DNA repair. Polyubiquitylation, in contrast, involves the formation of ubiquitin chains linked through specific lysine residues (such as K48 or K63). K48‑linked chains typically signal for proteasomal degradation, while K63‑linked chains regulate signalling pathways, DNA damage responses, and protein–protein interactions. This diversity enables ubiquitylation to function as a molecular code that directs proteins toward distinct cellular outcomes.
- Ubiquitylation plays a central role in protein degradation through the ubiquitin–proteasome system (UPS). Proteins tagged with K48‑linked ubiquitin chains are recognised by the 26S proteasome, unfolded, and degraded into peptides. This selective turnover ensures that damaged, misfolded, or short‑lived regulatory proteins are removed efficiently. The UPS regulates cell‑cycle progression by degrading cyclins, controls transcription by removing transcription factors, and shapes immune responses by generating antigenic peptides for MHC class I presentation.
- Beyond degradation, ubiquitylation is essential for signal transduction. Many signalling pathways rely on ubiquitin chains to activate or terminate responses. In the NF‑κB pathway, ubiquitylation of IκB triggers its degradation, allowing NF‑κB to enter the nucleus and initiate transcription. K63‑linked ubiquitylation of adaptor proteins such as TRAF6 amplifies innate immune signalling. These modifications ensure that signals are precisely timed and appropriately integrated into cellular behaviour.
- Ubiquitylation also regulates DNA damage repair. Ubiquitin modification of histones alters chromatin structure, enabling repair proteins to access damaged sites. Specific E3 ligases ubiquitylate repair factors to coordinate homologous recombination and non‑homologous end joining. This regulation maintains genomic stability and prevents mutations that contribute to cancer and ageing.
- Because ubiquitylation is reversible, deubiquitinating enzymes (DUBs) remove ubiquitin from substrates, rescuing proteins from degradation or altering their signalling roles. The balance between ubiquitylation and deubiquitylation ensures dynamic control over protein fate. Dysregulation of this balance contributes to neurodegeneration, cancer, immune disorders, and metabolic diseases.
- Overall, ubiquitylation is a fundamental regulatory mechanism that shapes nearly every aspect of cellular physiology. Its ability to modify proteins with precision and versatility makes it essential for maintaining homeostasis, responding to stress, and coordinating complex biological pathways. Understanding ubiquitylation provides deep insight into disease mechanisms and offers powerful opportunities for therapeutic innovation.